Therapure Drug Development
Pipeline
Therapure currently has four therapeutic products in its drug development pipeline.
Our Pipeline:
TBI 301
Indication: Post-Liver transplant & acute and chronic HCV
(Hepatitis CV)
We have developed a smarter way to target HCV infections with the best available drug. TBI 301 is a conjugate of hemoglobin and ribavirin that selectively targets the liver. The combination is more tolerable and powerful than ribavirin alone and has the potential to more effectively treat this widespread, serious and difficult to treat disease. TBI 301 is in position to commence human clinical trials following formal PK/Tox studies.
Indication: Post-Liver transplant & acute and chronic HCV
(Hepatitis CV)
We have developed a smarter way to target HCV infections with the best available drug. TBI 301 is a conjugate of hemoglobin and ribavirin that selectively targets the liver. The combination is more tolerable and powerful than ribavirin alone and has the potential to more effectively treat this widespread, serious and difficult to treat disease. TBI 301 is in position to commence human clinical trials following formal PK/Tox studies.
TBI 302
Indication: Hepatocellular carcinoma & metastatic colorectal cancer
TBI 302, a conjugate of hemoglobin and floxuridine, delivers this powerful chemotherapy agent directly to the liver, while also targeting liver metastases. TBI 302 is currently undergoing formal toxicity studies in preparation for a Phase I IND.
Image showing selective liver
uptake of radiolabeled hemoglobin
uptake of radiolabeled hemoglobin
TBI 303
Indication: Multiple
TBI 303 is a novel, proprietary protein modification technology designed to improve the performance of existing protein-based therapeutics through an increase in half-life. Screening studies currently underway at Therapure are designed to broaden the platform to a wide range of proteins.
TBI 304
Indication: Chemotherapy-Induced Anemia
Approximately 40% of people suffering from anemia, as a result of chemotherapy, do not respond to the current standard treatment, Erythropoietin. TBI 304 is a monoclonal antibody that mimics the natural ability of hemoglobin to stimulate blood forming stem cells to produce red blood cells. TBI 304 is currently in preclinical proof of concept stage.
Our Drug Development Team
Therapure's drug development team is led by Dr. David Bell, Vice President of Drug Development and Chief Scientific Officer and Dr. Gord Adamson, Director of Drug Development with support from Dr. Steve Brookes, Manager of Drug Development and Ms. Kate Matthews, Group Leader of Cell and Molecular Biology.
With more than 20 years of experience developing hemoglobin based therapeutics, we have first hand knowledge working with blood proteins in the lab. We have 8 clinical trials under our belt, and bring true expertise to protein modification, drug targeting and cell stimulation.
For more information about our pipeline, please contact Dr. David Bell, Vice President of Drug Development and Chief Scientific Officer.